Would you change systemic therapy for metastatic melanoma on BRAF/MEK targeted therapy with excellent extracranial response, but with CNS-only progression?
Answer from: Medical Oncologist at Academic Institution
If a patient is on BRAF/MEK dual targeted therapy with excellent extracranial response, but with CNS progression, I would favor continuing the BRAF/MEK inhibitor therapy and considering SRS to CNS lesion(s). However, if the patient has not received prior combination IO, another option to consider wo...
Comments
Medical Oncologist at University of Virginia Agree with the above, both options are reasonable ...
Medical Oncologist at Rocky Mountain Cancer Centers-Boulder How would you think about the patient with multipl...
Agree with the above, both options are reasonable ...
How would you think about the patient with multipl...